Advanced or Metastatic Breast Cancer

Oncology·MeSH: Breast Neoplasms

Prevalence

287.0 / 100K

Incidence

128.0 / 100K/yr

12 drugs in development·9 companies·2 clinical trials

Drug Pipeline by Phase

Approved(5)

Phase 3(6)

Drug	Company
Capivasertib	ASTRAZENECA PLC (AZN)
elacestrant	Radius Health, Inc. (RDUS)
Giredestrant	ENANTA PHARMACEUTICALS INC (ENTA)
GnRH Agonist	ENANTA PHARMACEUTICALS INC (ENTA)
LHRH Agonist	ENANTA PHARMACEUTICALS INC (ENTA)
PF-07220060 CDK4 inhibitor	Merus N.V. (MRUS)

Phase 2(1)

Drug	Company
ngc-cap	Processa Pharmaceuticals, Inc. (PCSA)

BioSniper tracks 12 drugs in development for Advanced or Metastatic Breast Cancer across 9 companies.

There are 2 clinical trials targeting Advanced or Metastatic Breast Cancer tracked by BioSniper.

The estimated prevalence of Advanced or Metastatic Breast Cancer is approximately 287.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.